48 results
Page 2 of 3
8-K
EX-10.1
rpja n3xet
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-99.1
6flhe75i7vroxr0jk 1k
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
424B5
4yw gph9fa7
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
4lqmpfoxo9f23
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
3hhomoyv2cldb2r5c
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
oehhq8n aq6
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
kxbxv wlcl58ma
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.2
cm8wy 1v6mg3x
23 Nov 20
Consolidated Financial Statements
12:00am
424B3
jsrn16gwhepogxqwh
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
tbfj11r25a3
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
qnw yg637diagcl3nn1e
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
lcfgsst5
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
i1uwiehu 0h3492y1iy
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.2
ta2c2g d6
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.4
phgow8zp
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm